PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
SNDX vs. VKTX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between SNDX and VKTX is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

SNDX vs. VKTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Syndax Pharmaceuticals, Inc. (SNDX) and Viking Therapeutics, Inc. (VKTX). The values are adjusted to include any dividend payments, if applicable.

-40.00%-20.00%0.00%20.00%40.00%AugustSeptemberOctoberNovemberDecember2025
-41.23%
-30.75%
SNDX
VKTX

Key characteristics

Sharpe Ratio

SNDX:

-0.76

VKTX:

0.72

Sortino Ratio

SNDX:

-0.87

VKTX:

2.66

Omega Ratio

SNDX:

0.88

VKTX:

1.34

Calmar Ratio

SNDX:

-0.69

VKTX:

1.82

Martin Ratio

SNDX:

-1.83

VKTX:

3.17

Ulcer Index

SNDX:

21.55%

VKTX:

34.24%

Daily Std Dev

SNDX:

51.88%

VKTX:

149.83%

Max Drawdown

SNDX:

-78.98%

VKTX:

-90.41%

Current Drawdown

SNDX:

-52.35%

VKTX:

-57.04%

Fundamentals

Market Cap

SNDX:

$1.18B

VKTX:

$4.52B

EPS

SNDX:

-$3.64

VKTX:

-$0.94

PEG Ratio

SNDX:

0.00

VKTX:

-0.03

Total Revenue (TTM)

SNDX:

$16.00M

VKTX:

$0.00

Gross Profit (TTM)

SNDX:

-$28.34M

VKTX:

-$236.00K

EBITDA (TTM)

SNDX:

-$224.46M

VKTX:

-$104.61M

Returns By Period

In the year-to-date period, SNDX achieves a 4.46% return, which is significantly higher than VKTX's 0.89% return.


SNDX

YTD

4.46%

1M

-11.25%

6M

-39.14%

1Y

-39.00%

5Y*

10.02%

10Y*

N/A

VKTX

YTD

0.89%

1M

-19.36%

6M

-29.99%

1Y

88.31%

5Y*

39.49%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

SNDX vs. VKTX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SNDX
The Risk-Adjusted Performance Rank of SNDX is 1010
Overall Rank
The Sharpe Ratio Rank of SNDX is 1111
Sharpe Ratio Rank
The Sortino Ratio Rank of SNDX is 1414
Sortino Ratio Rank
The Omega Ratio Rank of SNDX is 1414
Omega Ratio Rank
The Calmar Ratio Rank of SNDX is 99
Calmar Ratio Rank
The Martin Ratio Rank of SNDX is 22
Martin Ratio Rank

VKTX
The Risk-Adjusted Performance Rank of VKTX is 8383
Overall Rank
The Sharpe Ratio Rank of VKTX is 7373
Sharpe Ratio Rank
The Sortino Ratio Rank of VKTX is 8989
Sortino Ratio Rank
The Omega Ratio Rank of VKTX is 8787
Omega Ratio Rank
The Calmar Ratio Rank of VKTX is 9090
Calmar Ratio Rank
The Martin Ratio Rank of VKTX is 7676
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

SNDX vs. VKTX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Syndax Pharmaceuticals, Inc. (SNDX) and Viking Therapeutics, Inc. (VKTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for SNDX, currently valued at -0.76, compared to the broader market-4.00-2.000.002.00-0.760.72
The chart of Sortino ratio for SNDX, currently valued at -0.87, compared to the broader market-4.00-2.000.002.004.00-0.872.66
The chart of Omega ratio for SNDX, currently valued at 0.88, compared to the broader market0.501.001.502.000.881.34
The chart of Calmar ratio for SNDX, currently valued at -0.69, compared to the broader market0.002.004.006.00-0.691.82
The chart of Martin ratio for SNDX, currently valued at -1.83, compared to the broader market-10.000.0010.0020.00-1.833.17
SNDX
VKTX

The current SNDX Sharpe Ratio is -0.76, which is lower than the VKTX Sharpe Ratio of 0.72. The chart below compares the historical Sharpe Ratios of SNDX and VKTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.005.00AugustSeptemberOctoberNovemberDecember2025
-0.76
0.72
SNDX
VKTX

Dividends

SNDX vs. VKTX - Dividend Comparison

Neither SNDX nor VKTX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

SNDX vs. VKTX - Drawdown Comparison

The maximum SNDX drawdown since its inception was -78.98%, smaller than the maximum VKTX drawdown of -90.41%. Use the drawdown chart below to compare losses from any high point for SNDX and VKTX. For additional features, visit the drawdowns tool.


-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%AugustSeptemberOctoberNovemberDecember2025
-52.35%
-57.04%
SNDX
VKTX

Volatility

SNDX vs. VKTX - Volatility Comparison

The current volatility for Syndax Pharmaceuticals, Inc. (SNDX) is 16.96%, while Viking Therapeutics, Inc. (VKTX) has a volatility of 23.97%. This indicates that SNDX experiences smaller price fluctuations and is considered to be less risky than VKTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%30.00%35.00%AugustSeptemberOctoberNovemberDecember2025
16.96%
23.97%
SNDX
VKTX

Financials

SNDX vs. VKTX - Financials Comparison

This section allows you to compare key financial metrics between Syndax Pharmaceuticals, Inc. and Viking Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab